Which has stronger valuation & earnings, MEDP or CHE?

Medpace has higher revenue and earnings than Chemed. Chemed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 6.51 $451.12M $17.06 34.62 Chemed $2.53B 2.84 $265.24M $19.91 27.62

Is MEDP or CHE more profitable?

Medpace has a net margin of 17.67% compared to Chemed's net margin of 10.60%. Medpace's return on equity of 110.15% beat Chemed's return on equity. Company Net Margins Return on Equity Return on Assets Medpace 17.67% 110.15% 24.84% Chemed 10.60% 31.77% 18.90%

Does the media favor MEDP or CHE?

In the previous week, Chemed had 5 more articles in the media than Medpace. MarketBeat recorded 14 mentions for Chemed and 9 mentions for Medpace. Medpace's average media sentiment score of 1.07 beat Chemed's score of 0.73 indicating that Medpace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Chemed 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, CHE or DGX?

Quest Diagnostics has higher revenue and earnings than Chemed. Quest Diagnostics is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemed $2.53B 2.84 $265.24M $19.91 27.62 Quest Diagnostics $11.04B 2.38 $992M $9.42 25.23

Is CHE or DGX more profitable?

Chemed has a net margin of 10.60% compared to Quest Diagnostics' net margin of 9.18%. Chemed's return on equity of 31.77% beat Quest Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Chemed 10.60% 31.77% 18.90% Quest Diagnostics 9.18% 16.01% 7.27%

Does the media refer more to CHE or DGX?

In the previous week, Chemed had 9 more articles in the media than Quest Diagnostics. MarketBeat recorded 14 mentions for Chemed and 5 mentions for Quest Diagnostics. Quest Diagnostics' average media sentiment score of 1.31 beat Chemed's score of 0.73 indicating that Quest Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemed 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quest Diagnostics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, LH or CHE?

Labcorp has higher revenue and earnings than Chemed. Labcorp is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Labcorp $13.95B 1.85 $876.50M $12.09 26.38 Chemed $2.53B 2.84 $265.24M $19.91 27.62

Is LH or CHE more profitable?

Chemed has a net margin of 10.60% compared to Labcorp's net margin of 6.99%. Chemed's return on equity of 31.77% beat Labcorp's return on equity. Company Net Margins Return on Equity Return on Assets Labcorp 6.99% 16.74% 7.81% Chemed 10.60% 31.77% 18.90%

Does the media prefer LH or CHE?

In the previous week, Labcorp had 2 more articles in the media than Chemed. MarketBeat recorded 16 mentions for Labcorp and 14 mentions for Chemed. Chemed's average media sentiment score of 0.73 beat Labcorp's score of 0.69 indicating that Chemed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Labcorp 5 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Chemed 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, GH or CHE?

Chemed has higher revenue and earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Guardant Health $982.02M 22.93 -$416.28M -$3.49 N/A Chemed $2.53B 2.84 $265.24M $19.91 27.62

Does the media favor GH or CHE?

In the previous week, Guardant Health had 6 more articles in the media than Chemed. MarketBeat recorded 20 mentions for Guardant Health and 14 mentions for Chemed. Guardant Health's average media sentiment score of 0.90 beat Chemed's score of 0.73 indicating that Guardant Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Guardant Health 13 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Chemed 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, DVA or CHE?

DaVita has higher revenue and earnings than Chemed. DaVita is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DaVita $13.64B 0.85 $746.80M $12.22 14.86 Chemed $2.53B 2.84 $265.24M $19.91 27.62

Is DVA or CHE more profitable?

Chemed has a net margin of 10.60% compared to DaVita's net margin of 6.05%. Chemed's return on equity of 31.77% beat DaVita's return on equity. Company Net Margins Return on Equity Return on Assets DaVita 6.05% -217.63% 5.07% Chemed 10.60% 31.77% 18.90%

Does the media favor DVA or CHE?

In the previous week, DaVita had 17 more articles in the media than Chemed. MarketBeat recorded 31 mentions for DaVita and 14 mentions for Chemed. Chemed's average media sentiment score of 0.73 beat DaVita's score of 0.59 indicating that Chemed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DaVita 11 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive Chemed 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Chemed (CHE) Competitors

$549.93 -2.79 (-0.50%)

As of 09:32 AM Eastern

Compare

CHE vs. MEDP, DGX, LH, GH, and DVA

Should you buy Chemed stock or one of its competitors? MarketBeat compares Chemed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Chemed include Medpace (MEDP), Quest Diagnostics (DGX), Labcorp (LH), Guardant Health (GH), and DaVita (DVA). These companies are all part of the "healthcare" sector.

How does Chemed compare to Medpace?

Medpace (NASDAQ:MEDP) and Chemed (NYSE:CHE) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

78.0% of Medpace shares are held by institutional investors. Comparatively, 95.9% of Chemed shares are held by institutional investors. 20.5% of Medpace shares are held by company insiders. Comparatively, 3.3% of Chemed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Medpace currently has a consensus target price of $584.18, indicating a potential downside of 1.09%. Chemed has a consensus target price of $530.75, indicating a potential downside of 3.49%. Given Medpace's higher probable upside, analysts plainly believe Medpace is more favorable than Chemed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.15
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

Medpace has higher revenue and earnings than Chemed. Chemed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	6.51	$451.12M	$17.06	34.62
Chemed	$2.53B	2.84	$265.24M	$19.91	27.62

Medpace has a net margin of 17.67% compared to Chemed's net margin of 10.60%. Medpace's return on equity of 110.15% beat Chemed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.67%	110.15%	24.84%
Chemed	10.60%	31.77%	18.90%

Medpace has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, Chemed has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market.

In the previous week, Chemed had 5 more articles in the media than Medpace. MarketBeat recorded 14 mentions for Chemed and 9 mentions for Medpace. Medpace's average media sentiment score of 1.07 beat Chemed's score of 0.73 indicating that Medpace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Chemed	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Medpace beats Chemed on 12 of the 16 factors compared between the two stocks.

How does Chemed compare to Quest Diagnostics?

Chemed (NYSE:CHE) and Quest Diagnostics (NYSE:DGX) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

Chemed has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Quest Diagnostics has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

95.9% of Chemed shares are held by institutional investors. Comparatively, 88.1% of Quest Diagnostics shares are held by institutional investors. 3.3% of Chemed shares are held by insiders. Comparatively, 0.9% of Quest Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Chemed has a net margin of 10.60% compared to Quest Diagnostics' net margin of 9.18%. Chemed's return on equity of 31.77% beat Quest Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemed	10.60%	31.77%	18.90%
Quest Diagnostics	9.18%	16.01%	7.27%

Quest Diagnostics has higher revenue and earnings than Chemed. Quest Diagnostics is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemed	$2.53B	2.84	$265.24M	$19.91	27.62
Quest Diagnostics	$11.04B	2.38	$992M	$9.42	25.23

In the previous week, Chemed had 9 more articles in the media than Quest Diagnostics. MarketBeat recorded 14 mentions for Chemed and 5 mentions for Quest Diagnostics. Quest Diagnostics' average media sentiment score of 1.31 beat Chemed's score of 0.73 indicating that Quest Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemed	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quest Diagnostics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Chemed pays an annual dividend of $2.40 per share and has a dividend yield of 0.4%. Quest Diagnostics pays an annual dividend of $3.44 per share and has a dividend yield of 1.4%. Chemed pays out 12.1% of its earnings in the form of a dividend. Quest Diagnostics pays out 36.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Chemed has raised its dividend for 16 consecutive years and Quest Diagnostics has raised its dividend for 14 consecutive years.

Chemed presently has a consensus price target of $530.75, indicating a potential downside of 3.49%. Quest Diagnostics has a consensus price target of $235.31, indicating a potential downside of 1.00%. Given Quest Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe Quest Diagnostics is more favorable than Chemed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46

Summary

Chemed beats Quest Diagnostics on 11 of the 19 factors compared between the two stocks.

How does Chemed compare to Labcorp?

Labcorp (NYSE:LH) and Chemed (NYSE:CHE) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

In the previous week, Labcorp had 2 more articles in the media than Chemed. MarketBeat recorded 16 mentions for Labcorp and 14 mentions for Chemed. Chemed's average media sentiment score of 0.73 beat Labcorp's score of 0.69 indicating that Chemed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Labcorp	5 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Chemed	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Labcorp has higher revenue and earnings than Chemed. Labcorp is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Labcorp	$13.95B	1.85	$876.50M	$12.09	26.38
Chemed	$2.53B	2.84	$265.24M	$19.91	27.62

Labcorp currently has a consensus price target of $326.82, indicating a potential upside of 2.46%. Chemed has a consensus price target of $530.75, indicating a potential downside of 3.49%. Given Labcorp's stronger consensus rating and higher probable upside, analysts clearly believe Labcorp is more favorable than Chemed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Labcorp	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

Labcorp pays an annual dividend of $2.88 per share and has a dividend yield of 0.9%. Chemed pays an annual dividend of $2.40 per share and has a dividend yield of 0.4%. Labcorp pays out 23.8% of its earnings in the form of a dividend. Chemed pays out 12.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Chemed has raised its dividend for 16 consecutive years.

Labcorp has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market. Comparatively, Chemed has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

Chemed has a net margin of 10.60% compared to Labcorp's net margin of 6.99%. Chemed's return on equity of 31.77% beat Labcorp's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Labcorp	6.99%	16.74%	7.81%
Chemed	10.60%	31.77%	18.90%

95.9% of Labcorp shares are owned by institutional investors. Comparatively, 95.9% of Chemed shares are owned by institutional investors. 0.8% of Labcorp shares are owned by company insiders. Comparatively, 3.3% of Chemed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Chemed beats Labcorp on 10 of the 19 factors compared between the two stocks.

How does Chemed compare to Guardant Health?

Guardant Health (NASDAQ:GH) and Chemed (NYSE:CHE) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

Guardant Health has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market. Comparatively, Chemed has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market.

92.6% of Guardant Health shares are held by institutional investors. Comparatively, 95.9% of Chemed shares are held by institutional investors. 5.6% of Guardant Health shares are held by insiders. Comparatively, 3.3% of Chemed shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Chemed has a net margin of 10.60% compared to Guardant Health's net margin of -38.33%. Chemed's return on equity of 31.77% beat Guardant Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Guardant Health	-38.33%	N/A	-25.40%
Chemed	10.60%	31.77%	18.90%

Chemed has higher revenue and earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Guardant Health	$982.02M	22.93	-$416.28M	-$3.49	N/A
Chemed	$2.53B	2.84	$265.24M	$19.91	27.62

Guardant Health currently has a consensus price target of $183.78, suggesting a potential upside of 9.51%. Chemed has a consensus price target of $530.75, suggesting a potential downside of 3.49%. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts plainly believe Guardant Health is more favorable than Chemed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guardant Health	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

In the previous week, Guardant Health had 6 more articles in the media than Chemed. MarketBeat recorded 20 mentions for Guardant Health and 14 mentions for Chemed. Guardant Health's average media sentiment score of 0.90 beat Chemed's score of 0.73 indicating that Guardant Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Guardant Health	13 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Chemed	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Guardant Health beats Chemed on 9 of the 17 factors compared between the two stocks.

How does Chemed compare to DaVita?

DaVita (NYSE:DVA) and Chemed (NYSE:CHE) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

DaVita has higher revenue and earnings than Chemed. DaVita is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DaVita	$13.64B	0.85	$746.80M	$12.22	14.86
Chemed	$2.53B	2.84	$265.24M	$19.91	27.62

DaVita has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Chemed has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

DaVita presently has a consensus price target of $221.75, suggesting a potential upside of 22.15%. Chemed has a consensus price target of $530.75, suggesting a potential downside of 3.49%. Given DaVita's stronger consensus rating and higher possible upside, research analysts clearly believe DaVita is more favorable than Chemed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DaVita	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

Chemed has a net margin of 10.60% compared to DaVita's net margin of 6.05%. Chemed's return on equity of 31.77% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DaVita	6.05%	-217.63%	5.07%
Chemed	10.60%	31.77%	18.90%

In the previous week, DaVita had 17 more articles in the media than Chemed. MarketBeat recorded 31 mentions for DaVita and 14 mentions for Chemed. Chemed's average media sentiment score of 0.73 beat DaVita's score of 0.59 indicating that Chemed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DaVita	11 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive
Chemed	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

90.1% of DaVita shares are held by institutional investors. Comparatively, 95.9% of Chemed shares are held by institutional investors. 1.9% of DaVita shares are held by insiders. Comparatively, 3.3% of Chemed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Chemed beats DaVita on 9 of the 16 factors compared between the two stocks.

Get Chemed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CHE vs. The Competition

Export

Metric	Chemed	Healthcare Providers & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$7.21B	$9.94B	$7.00B	$24.11B
Dividend Yield	0.43%	2.55%	2.58%	3.69%
P/E Ratio	27.72	25.11	270.57	29.19
Price / Sales	2.84	4.81	659.56	13.03
Price / Cash	22.41	25.58	28.89	19.37
Price / Book	7.95	5.33	11.20	4.91
Net Income	$265.24M	$309.96M	$3.45B	$1.06B
7 Day Performance	1.67%	0.84%	3.39%	1.65%
1 Month Performance	12.75%	0.34%	-0.72%	2.63%
1 Year Performance	26.18%	22.92%	77.42%	20.40%

Chemed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CHE Chemed	3.8274 of 5 stars	$549.94 -0.5%	$530.75 -3.5%	+26.7%	$7.21B	$2.53B	27.72	15,811	Dividend Increase
MEDP Medpace	2.651 of 5 stars	$573.29 -0.7%	$584.18 +1.9%	+36.0%	$16.11B	$2.53B	33.60	6,200	Positive News
DGX Quest Diagnostics	4.2578 of 5 stars	$231.95 -0.5%	$235.31 +1.4%	+34.3%	$25.72B	$11.04B	24.62	57,000	Positive News
LH Labcorp	3.3821 of 5 stars	$307.45 -0.6%	$326.00 +6.0%	+19.8%	$25.35B	$13.95B	25.43	71,000
GH Guardant Health	2.9541 of 5 stars	$158.83 -2.0%	$179.82 +13.2%	+210.7%	$21.74B	$982.02M	N/A	2,506	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CHE) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Chemed (CHE) Competitors